PTX3 and neoplasm: Indeed, tumor and/or host PTX3 overexpression can inhibit FGF-driven epithelial-to-mesenchymal transition (EMT) and tumor/metastatic burden in melanoma models [12] and hampers cancer growth in models of fibrosarcoma, prostate and bladder cancer [6, 8, 13].